Announcements
- Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
- Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
- Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
- Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
- Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
- Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
- Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
- Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
- Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
- Compass Pathways appoints Teri Loxam as Chief Financial Officer
More ▼
Key statistics
On Friday, Compass Pathways PLC (5Y6:MUN) closed at 6.35, 28.54% above the 52 week low of 4.94 set on Nov 14, 2023.
52-week range
Open | 6.35 |
---|---|
High | 6.35 |
Low | 6.35 |
Bid | 6.35 |
Offer | 6.45 |
Previous close | 6.85 |
Average volume | 1.65k |
---|---|
Shares outstanding | 68.38m |
Free float | 45.30m |
P/E (TTM) | -- |
Market cap | 524.48m USD |
EPS (TTM) | -2.37 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 07:05 BST.
More ▼